Steve Schonfeld’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.8M Buy
+118,227
New +$2.95M 0.01% 959
2025
Q3
– Sell
-52,340
Closed -$596K – 2449
2025
Q2
$596K Sell
52,340
-6,012
-10% -$65K ﹤0.01% 1490
2025
Q1
$693K Sell
58,352
-344,603
-86% -$5.76M ﹤0.01% 1443
2024
Q4
$7.59M Buy
402,955
+47,353
+13% +$1.09M 0.04% 380
2024
Q3
$7.99M Sell
355,602
-76,687
-18% -$1.74M 0.05% 364
2024
Q2
$9.02M Buy
432,289
+170,127
+65% +$2.65M 0.06% 377
2024
Q1
$3.85M Buy
+262,162
New +$2.82M 0.03% 740
2022
Q1
– Sell
-7,600
Closed -$220K – 2808
2021
Q4
$220K Buy
+7,600
New +$230K ﹤0.01% 1681

Other funds holding NRIX

Steve Schonfeld's NRIX Position: Q3 2026 in Review

Steve Schonfeld opened a new position in Nurix Therapeutics (NRIX) in Q3 2026: 118,227 shares worth $2.8M. The stake represents 0.01% of the portfolio and ranks #959 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in NRIX as recently as Q2 2025.

Steve Schonfeld first reported a position in NRIX in Q4 2021 and has held it in 8 quarters since. The position peaked at $9.02M in Q2 2024. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Steve Schonfeld held 118,227 shares of Nurix Therapeutics worth $2.8M as of Q3 2026.
  • Nurix Therapeutics was a new Steve Schonfeld position in Q3 2026.
  • Nurix Therapeutics made up 0.01% of Steve Schonfeld's portfolio in Q3 2026, its #959 holding.
  • Steve Schonfeld first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • Steve Schonfeld's Nurix Therapeutics position peaked at $9.02M in Q2 2024.
  • 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.